Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SilkPlatelet

Financiado

Closing the European gap towards a large scale ex vivo platelet production built...

Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactor The generation of ex vivo functional megakaryocytes (MK) and platelets is questioning current transfusion medicine exclusive reliance on blood donors to produce platelets. The demand for platelets is, in fact, in continuous rise,... ver más

30/09/2025

UNIPV

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PAVIA No se ha especificado una descripción o un objeto social para esta compañía.

Ver 6 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-07-25

HORIZON-EIC-2021-TRANSITIONCHALLENGES-01-01: Medical Technology and Devices: fro... Scope:EU-funded early-stage Research on novel Medical Technologies and Devices is uncovering unique...

I+D

Cerrada hace 3 años

0% 100%

6 Participantes

UNIPV

810.38K€ | Lider

INSTITUT GUSTAVE ROUSSY

498.63K€ | Participante

THE CHANCELLOR MASTERS AND S...

N.D. | Participante

Radboud University of Nijmeg...

91.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2015-72617-EXP REPROGRAMACION Y REGENERACION TISULAR A PARTIR DE MICROVESIC... 48K€ Cerrado

hOssicle Bioengineering of human ossicles as advanced in vivo hematop... 2M€ Cerrado

SAF2011-22576 BIONGENIERIA DEL PULMON MEDIANTE CULTIVO DE CELULAS MADRE EN... 127K€ Cerrado

FJCI-2016-30387 Ingeniería de Tejidos 50K€ Cerrado

REBORN Full human based multi scale constructs with jammed regenera... 2M€ Cerrado

EUIN2013-50760 CARDIAC REGENERATION TECHNOLOGY 25K€ Cerrado

Duración del proyecto: 38 meses Fecha Inicio: 2022-07-25
Fecha Fin: 2025-09-30

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PAVIA No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Descripción del proyecto The generation of ex vivo functional megakaryocytes (MK) and platelets is questioning current transfusion medicine exclusive reliance on blood donors to produce platelets. The demand for platelets is, in fact, in continuous rise, driven by an aging population, advances in medical procedures and even more aggressive cancer therapies, although the supply of blood donors continues to remain stagnant. Ex vivo platelet production systems have then emerged as a feasible supply that can moreover secure universal compatibility to avoid platelet refractoriness. If during the FET Open application we have proved that the platelet production ex vivo can be precision-tailored with the correct physical and biochemical environment, now with SilkPlatelet our consortium is looking forward to demonstrating the feasibility of an upscaled ex vivo production system. To bring then our technology from TRL4 to TRL6 we will increase the ex vivo platelet production capacity with media and stem cells aligned to GMP requirements for large-scale clinical transfusion. Our goal is to produce universal platelets particularly for patients with immune reaction to previous transfusions with HLA null platelets and patients with acute hemorrhage. At the core of our ?from lab-to-patients? roadmap, we will find both UNICAM proprietary technology to differentiate stem cells into MK precursors (natural source of platelets) and UNIPV disruptive bioreactor made of a silk-scaffold to mimic the bone marrow conditions. These will be then complemented by IGR long-term experience in iPSC and MK biology, and ISENET cell quality control contribute to the standardization of the platelet production pipeline and its validation and verification. Under the guidance of our experienced tech transfer officers, by the end of the project we expect to complete the transition into a commercial innovation exploited by a next university spin-out.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores